LivaNova’s VNS Therapy Shows Sustained Effectiveness in Drug-Resistant Epilepsy

LivaNova (NASDAQ:LIVN) is one of the best mid cap pharma stocks to buy. Earlier in June, LivaNova announced the completion of its CORE-VNS study, which is a significant real-world evidence evaluation of its VNS Therapy device for individuals with epilepsy. This add-on treatment is designed to reduce seizure frequency in patients aged four and older who experience drug-resistant epilepsy/DRE and partial-onset seizures.

The study collected data from over 800 participants across 61 sites globally and generated final 36-month data confirming the therapy’s early and sustained effectiveness on severe focal seizures in both pediatric and adult patients with DRE. The full 36-month CORE-VNS study results are expected to be published later in 2025. One finding from the study highlighted the therapy’s impact on focal onset seizures with impaired awareness/FIA, identified as the most disabling seizure type for the majority of subjects across all ages.

A close-up of a medical device used for therapeutic solutions in a world-class hospital.

The study also showed benefits for focal to bilateral tonic-clonic/FBTC seizures. The positive effects of VNS Therapy were observed as early as 3 months post-implantation, with continued reductions in both FIA and FBTC seizures at subsequent 12, 24, and 36-month visits. The CORE-VNS study maintained a high patient retention rate of 82% throughout the 3-year follow-up period.

LivaNova (NASDAQ:LIVN) is a medical technology company that designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.